Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P4WO
|
|||
| Former ID |
DCL000031
|
|||
| Drug Name |
ADX10059
|
|||
| Indication | Anxiety disorder [ICD-11: 6B00-6B0Z; ICD-10: R45.0] | Phase 2 | [1] | |
| Company |
Addex Pharma.
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00820105) ADX10059 Migraine Prevention Study. U.S. National Institutes of Health. | |||
| REF 2 | A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and... Gut. 2009 Sep;58(9):1192-9. | |||
| REF 3 | Novel treatments of GERD: focus on the lower esophageal sphincter. Eur Rev Med Pharmacol Sci. 2008 Aug;12 Suppl 1:103-10. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.